U.S. Telecom Services and Carriers Stock News

NasdaqGS:AKAM
NasdaqGS:AKAMIT

A Look At Akamai Technologies (AKAM) Valuation As Earnings Optimism And Arrow Partnership Lift Investor Interest

Akamai Technologies (AKAM) is back in focus after renewed optimism around its upcoming quarterly earnings, supported by a positive Earnings ESP, recent estimate beats, analyst upgrades, and a new cloud partnership with Arrow Electronics. See our latest analysis for Akamai Technologies. Akamai’s share price has been choppy recently, with a 9.05% 7 day share price return following a 11.97% 30 day share price decline. However, the year to date share price return of 22.06% and 1 year total...
NYSE:ASH
NYSE:ASHChemicals

Does Ashland's (ASH) Trimmed Sales Outlook and Buybacks Recast Its Margin-Resilience Story?

In the past week, Ashland Inc. reported second-quarter fiscal 2026 results showing sales of US$482 million and net income of US$16 million, alongside updated full-year 2026 sales guidance to a range of US$1,835 million to US$1,870 million. The company also confirmed it has now completed its June 28, 2023 share repurchase program, having bought back 5,826,514 shares for US$480.07 million, reshaping its capital allocation profile as it contends with softer demand and operational headwinds. Now...
NasdaqGS:WYNN
NasdaqGS:WYNNHospitality

Does Legionnaires’ Probe at Wynn Las Vegas Change The Bull Case For Wynn Resorts (WYNN)?

In late April 2026, health officials linked two past cases of Legionnaires’ disease to stays at Wynn Las Vegas, prompting a formal investigation and extensive water-system remediation that recent tests indicate has removed detectable Legionella bacteria. The episode highlights how health and safety issues at a flagship property can quickly become a material operational and reputational consideration for a global resort operator like Wynn Resorts. We’ll now examine how this Legionnaires’...
NYSE:HAYW
NYSE:HAYWBuilding

A Look At Hayward Holdings (HAYW) Valuation After Strong Q1 Beat And Upgraded 2026 Guidance

Hayward Holdings (HAYW) just released first quarter 2026 results that beat market expectations, reporting double digit revenue and earnings growth, and raised full year sales and earnings guidance for 2026. See our latest analysis for Hayward Holdings. After these stronger than expected results and higher guidance, Hayward’s 1 month share price return of 12.48% stands out against a weaker 90 day share price return of a 6.52% decline and a 5 year total shareholder return of a 35.77% decline,...
NasdaqGS:SWKS
NasdaqGS:SWKSSemiconductor

Is Skyworks (SWKS) Using Integrated Isolators To Quietly Rewire Its Industrial And Auto Narrative?

In late April 2026, Skyworks Solutions announced the Si86Px family of digital isolators with integrated power, combining high-performance digital isolation, an onboard isolated dc-dc converter delivering up to 0.5 W, and compact WB SOIC-16/20 packaging for space‑constrained industrial and automotive designs. By tightly integrating signal and power isolation with industry‑leading 0.1% typical load regulation and 150 Mbps data rates, Skyworks is positioning its isolator portfolio for demanding...
NYSE:BMY
NYSE:BMYPharmaceuticals

A Look At Bristol Myers Squibb (BMY) Valuation After Its Q1 2026 Earnings Beat And Reaffirmed Guidance

Bristol-Myers Squibb (BMY) reported first quarter 2026 results that came in ahead of analyst expectations, with double digit growth from its newer drugs and a reaffirmed full year 2026 outlook. See our latest analysis for Bristol-Myers Squibb. After an initial bounce on the Q1 beat and reaffirmed guidance, Bristol-Myers Squibb’s recent 1-day share price return of a 3.91% decline and 7-day share price return of a 0.83% decline contrast with its 8.90% year-to-date share price gain and 20.88%...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Structure Therapeutics previously reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans to meet the FDA in Q2 2026 ahead of Phase 3 trials in the second half of 2026. The data position aleniglipron as one of the most effective oral GLP-1 candidates so far, highlighting a potentially meaningful differentiation versus other pill-based obesity treatments. Next, we...
NYSE:RAMP
NYSE:RAMPSoftware

A Look At LiveRamp (RAMP) Valuation After GPU Optimized AI Clean Room Upgrade

AI clean rooms upgrade as a fresh catalyst LiveRamp Holdings (RAMP) is drawing attention after announcing native support for NVIDIA AI infrastructure, a move that refits its clean room architecture for more demanding, GPU-based AI marketing workloads. See our latest analysis for LiveRamp Holdings. The recent AI clean room upgrade arrives after a period of firm momentum, with a 90 day share price return of 23.26% and a 1 year total shareholder return of 13.91% from a last close of US$30.21...
NYSE:BHVN
NYSE:BHVNBiotechs

Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio

Recent share performance and business profile Biohaven (BHVN) has drawn investor attention after a period of weaker share returns, including an 18% decline over the past 3 months and a 57.86% drop over the past year. The company focuses on developing treatments across immunology, neuroscience, and oncology, with multiple drug candidates in Phase 2 and Phase 3 clinical trials. It has a market capitalization of about US$1.45b. See our latest analysis for Biohaven. At a share price of US$9.63,...
NasdaqGS:HAS
NasdaqGS:HASLeisure

Hasbro (HAS) Valuation In Focus As Recent Gains Contrast With Conflicting Fair Value Narratives

Hasbro stock performance snapshot Hasbro (HAS) has drawn fresh attention after recent share price moves, with the stock showing a 0.6% decline over the past day, along with gains of about 5.7% for the month and 1.5% over the past 3 months. See our latest analysis for Hasbro. Zooming out from the latest move, Hasbro’s 1 month share price return of 5.7% fits into a steadier upward trend. The year to date share price return is 14.8%, and the 1 year total shareholder return is 59.8%, suggesting...
NasdaqGS:CWST
NasdaqGS:CWSTCommercial Services

Casella Waste Systems (CWST) Is Up 8.3% After Mixed 2026 Outlook on Revenue Growth and Profit Pressures

In the past week, Casella Waste Systems reported first-quarter 2026 results with revenues rising to US$457.33 million from US$417.10 million a year earlier, while posting a net loss of US$5.54 million, and simultaneously raised its full-year 2026 revenue guidance to a range of US$2.06 billion to US$2.08 billion but reduced its net income outlook to US$4 million to US$10 million. The company’s performance was driven by higher pricing and four acquisitions so far in 2026, including the Star...
NYSE:CWK
NYSE:CWKReal Estate

How Cushman & Wakefield’s New Occupier Advisory Chair Role Will Impact Cushman & Wakefield (CWK) Investors

Cushman & Wakefield recently appointed industry veteran Tom Maloney as Chair of Occupier Advisory Services, tasking him with advancing enterprise strategy, talent development, and global client support from his base in Los Angeles. This leadership hire, coupled with optimistic analyst expectations for upcoming quarterly results, highlights how management bench strength is becoming central to the firm’s occupier-focused growth agenda. We’ll now examine how Maloney’s appointment to lead...
NYSE:UWMC
NYSE:UWMCDiversified Financial

Assessing UWM Holdings (UWMC) Valuation After Recent Weak Returns And AI Productivity Push

Why UWM Holdings Is Drawing Attention Now UWM Holdings (UWMC) has pulled back in the past 3 months, with the stock closing at US$3.66 and showing negative returns over the past year and year to date. See our latest analysis for UWM Holdings. The recent 3.39% 1 day share price gain comes after a 90 day share price return of 28.66% decline and a 1 year total shareholder return of 18.02% loss, suggesting momentum has been fading rather than building. If UWM Holdings has you reassessing where you...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

How Shoals’ Governance Rifts on Executive Pay and Board Equity Could Shape Shoals Technologies (SHLS)

Shoals Technologies Group recently held its 2026 Annual Meeting, re-electing five directors, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as auditor, while directors received new restricted stock unit grants with varying vesting and deferral schedules. The mixed shareholder support for executive compensation, alongside rising director equity stakes and Vanguard’s more than 5% ownership, highlights growing investor focus on governance and alignment of...
NYSE:DD
NYSE:DDChemicals

Is It Too Late To Consider DuPont De Nemours (DD) After Its 68% One-Year Rally?

Wondering whether DuPont de Nemours is still priced attractively after its recent run, or if the easy value has already been taken off the table. The stock last closed at US$46.24, with returns of 13.1% year to date and 67.8% over the past year, following a more muted 1.7% return over 30 days and a 0.2% slip over the last week. Recent news coverage has focused on DuPont de Nemours as a major name in the US materials space, with investors paying close attention to how the company positions...
NasdaqGS:CAPR
NasdaqGS:CAPRBiotechs

Capricor Therapeutics (CAPR) Is Down 12.4% After New HOPE-3 Deramiocel Phase 3 Data Release - What's Changed

Capricor Therapeutics recently presented Phase 3 HOPE-3 data for its Duchenne muscular dystrophy therapy Deramiocel at the 2026 American Academy of Neurology Annual Meeting, showing meaningful slowing of disease progression in upper limb function, including real-world self-feeding ability captured via home-based video assessment. With Deramiocel’s Biologics License Application already under FDA review and a PDUFA target action date of August 22, 2026, these data highlight its potential to...
NYSE:NEU
NYSE:NEUChemicals

Softer Q1 Results and Cash Returns Could Be A Game Changer For NewMarket (NEU)

NewMarket Corporation recently reported first-quarter 2026 results showing sales of US$669.72 million and net income of US$118.07 million, both lower than a year earlier, and its board declared a US$3.00 per-share dividend payable on July 1, 2026 to shareholders of record on June 15, 2026. Alongside these results, NewMarket completed a share repurchase of 337,201 shares for US$197.36 million, reducing its share count while continuing to return cash through dividends. We’ll now examine how...